Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY)

Harmony Biosciences Holdings Inc is a biopharmaceutical company dedicated to discovering and developing treatments for rare neurological diseases. The firm concentrates on sleep wake disorders rare epilepsy and neurobehavioral conditions. It describes itself as cultivating a differentiated neuroscience company rooted in innovation and driven by a commitment to addressing unmet patient needs. The lead product WAKIX pitolisant is a first in class histamine H3 receptor antagonist approved for excessive daytime sleepiness and cataplexy in narcolepsy. Beyond narcolepsy the company is advancing pitolisant for idiopathic hypersomnia Prader Willi syndrome and myotonic dystrophy type 1. Harmony Biosciences also expands its portfolio through acquisitions and licenses adding EPX 100 and EPX 200 for rare epilepsy syndromes and ZYN002 a synthetic cannabidiol gel for neurobehavioral indications. The company operates through its wholly owned subsidiaries Harmony Biosciences LLC and Harmony Biosciences Management Inc. Its strategy relies on licensing agreements with Bioprojet and other partners to secure exclusive development and commercialization rights in the United States and Latin America.

The company generates revenue primarily from the sale of its commercial product WAKIX. WAKIX is distributed through a limited number of specialty pharmacies and distributors that dispense the medication to patients based on prescriptions. In the year ended December 31 2025 net product revenue from WAKIX reached approximately eight hundred sixty eight point five million dollars. The firm also receives potential future income from licensing agreements milestone payments and royalties associated with its development pipeline but current product sales constitute the overwhelming majority of total revenue. The revenue stream is supported by a growing base of health care providers prescribing WAKIX and an increasing number of patients remaining on therapy over time.

Harmony Biosciences organizes its operations into three main therapeutic franchises Sleep Wake Franchise Rare Epilepsy Franchise and Neurobehavioral Franchise.

• The Sleep Wake Franchise centers on the commercialization and development of pitolisant based products. The flagship product WAKIX is a once daily oral tablet that enhances histamine signaling in the brain to treat excessive daytime sleepiness and cataplexy in narcolepsy patients. WAKIX has received approvals for adult and pediatric narcolepsy indications including excessive daytime sleepiness in adults approved 2019 cataplexy in adults approved 2020 excessive daytime sleepiness in pediatric patients six years and older approved 2024 and cataplexy in pediatric patients six years and older approved 2026. The franchise pursues label expansions for pitolisant in idiopathic hypersomnia Prader Willi syndrome and myotonic dystrophy type 1 supported by ongoing clinical programs. Additionally Harmony Biosciences is developing next generation formulations Pitolisant GR and Pitolisant HD and advancing an orexin 2 receptor agonist BP1 15205 for narcolepsy and other indications. The franchise also conducts exploratory studies of pitolisant for fatigue in larger central nervous system indications such as multiple sclerosis stroke and Parkinson disease.

• The Rare Epilepsy Franchise focuses on developing therapies for severe epileptic encephalopathies. The lead candidate EPX 100 is a serotonin 5HT 2 receptor agonist currently in two Phase 3 registrational trials one for Dravet Syndrome and one for Lennox Gastaut Syndrome. EPX 100 has received orphan drug and rare pediatric disease designations from the FDA for both indications. Another candidate EPX 200 is a selective 5HT 2C agonist in the pre IND stage targeting developmental and epileptic encephalopathies. The franchise estimates the total addressable market for EPX 100 to be approximately five thousand patients with Dravet Syndrome and thirty five thousand patients with Lennox Gastaut Syndrome based on diagnosed prevalence figures. Clinical data from the ARGUS study showed clinically meaningful reductions in seizure activity in participants with Dravet Syndrome and a favorable benefit risk profile. The LIGHTHOUSE study for Lennox Gastaut Syndrome is ongoing with anticipated data release in coming years.

• The Neurobehavioral Franchise leverages transdermal cannabidiol technology to address neurobehavioral symptoms. The primary asset ZYN002 is a synthetic cannabidiol gel designed for transdermal delivery in Fragile X Syndrome and other neurobehavioral conditions. A Phase 3 trial called RECONNECT evaluated ZYN002 for Fragile X Syndrome but did not meet its primary endpoint due to a higher than expected placebo response. Despite this outcome the company continues to explore ZYN002 in related disorders such as 22q deletion syndrome where an open label phase 2 proof of concept study showed positive signals for behavioral symptoms. The franchise also includes earlier stage programs like HBS 102 a melanin concentrating hormone receptor antagonist being evaluated for Prader Willi syndrome and other metabolic indications. Preclinical work on HBS 102 has shown consistent results in animal models and the company is pursuing additional toxicology studies to support future development.

Harmony Biosciences holds a differentiated position in the rare neurological disease market due to its non scheduled status for WAKIX which avoids the prescribing restrictions associated with controlled substances. The product is priced lower than sodium oxybate based therapies such as Xyrem and Xywav yet higher than generic stimulants like modafinil and armodafinil creating a distinct value proposition for payers and patients. Competitors include Jazz Pharmaceuticals with Xyrem Xywav and Sunosi Avadel Pharmaceuticals with a once nightly sodium oxybate formulation and various stimulant manufacturers such as Teva and Mylan. Additionally pipeline agents such as Axsome Therapeutics AXS 12 Suven Life Sciences SUVN G3031 mazindol ER and orexin 2 receptor agonists from Takeda Jazz Pharmaceuticals Sumitomo Pharma Centessa and Alkermes are under investigation for narcolepsy and related indications. The company's competitive advantages stem from its novel mechanism of action its once daily dosing its strong intellectual property portfolio covering pitolisant formulations and next generation candidates and its ability to offer a non scheduled treatment option that simplifies prescribing and reduces abuse potential.

The company sells WAKIX to a limited number of specialty distributors that in turn supply pharmacies and health care providers. For the year ended December 31 2025 three customers accounted for one hundred percent of gross product revenue. Caremark LLC contributed thirty eight percent Accredo Health Group Inc contributed thirty six percent and PANTHERx Specialty Pharmacy LLC contributed twenty six percent. These distributors serve a broad base of patients prescribed WAKIX for narcolepsy and related indications including excessive daytime sleepiness and cataplexy. The reliance on a small number of distributors reflects the specialty nature of the product and the need for careful handling and patient support services. Harmony Biosciences works closely with these partners to ensure reliable supply and appropriate patient access to its therapy.